{{Rsnum
|rsid=1920045
|Gene=CBX5
|Chromosome=12
|position=54276614
|Orientation=minus
|GMAF=0.4481
|Gene_s=CBX5
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 22.1 | 41.6 | 36.3
| HCB | 29.9 | 51.1 | 19.0
| JPT | 38.1 | 47.8 | 14.2
| YRI | 66.2 | 31.7 | 2.1
| ASW | 54.4 | 36.8 | 8.8
| CHB | 29.9 | 51.1 | 19.0
| CHD | 30.6 | 45.4 | 24.1
| GIH | 33.7 | 53.5 | 12.9
| LWK | 79.1 | 16.4 | 4.5
| MEX | 27.6 | 44.8 | 27.6
| MKK | 55.5 | 37.4 | 7.1
| TSI | 10.9 | 38.6 | 50.5
| HapMapRevision=28
}}
Associated with Heterogeneous nuclear ribonucleoprotein A1 ([[HNRNPA1]]) exon 8 alternative splicing. Study presents evidence that it is a sterol-regulated splicing factor that binds to [[HMGCR]] binding motif  at [[rs3846662]] in turn modulating its alternative splicing. Consistent with this evidence, [[rs1920045]] AA homozygote minor allele was found to modestly reduce the effectiveness of statins in lowering total plasma cholesterol in two independent clinical trials, CAP and PRINCE (P=0.006 combined)[[http://www.sciencedirect.com/science/article/pii/S1043661813002697]]. The study notes this SNP is in LD with [[HNRPA1]] promoter region, and therefore likely just tags the causal variant within the promoter region.
{{PMID Auto
|PMID=24001602
|Title=HNRNPA1 regulates HMGCR alternative splicing and modulates cellular cholesterol metabolism
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}